SCHEMBL6079807

SCHEMBL6079807

Nc1ccc(Cl)c(COc2ccccn2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.57
ALDH1A1 P00352 2/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C19 P33261 1/20 0.57
SYK P43405 1/20 0.54
RXRA P19793 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
HPGD P15428 1/20 0.39
HTR2C P28335 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
BCL2L1 Q07817 1/20 0.37
GRM5 P41594 1/20 0.37
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
MAOB P27338 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GABRA5 P31644 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079731 0.81 RXRA (0.40) NPC1ALDH1A1CYP2D6CYP2C19SYK
SCHEMBL13498434 0.79 NPC1 (0.62) NPC1ALDH1A1CYP2D6CYP2C19SYK
SCHEMBL13498015 0.78 ALDH1A1 (0.54) NPC1ALDH1A1CYP2D6CYP2C19SYK
SCHEMBL6080626 0.78 NPC1 (0.63) NPC1ALDH1A1SYKHPGDMAPT
SCHEMBL3387450 0.74 NPC1 (0.58) NPC1ALDH1A1CYP2D6CYP2C19MAPT
SCHEMBL6079265 0.74 NOS1 (0.47) SYKRXRAGRIN1GRIN2BMAPT
SCHEMBL27479330 0.73 CYP2D6 (0.58) NPC1ALDH1A1CYP2D6CYP2C19SYK
SCHEMBL30340760 0.73 ALDH1A1 (0.54) NPC1ALDH1A1CYP2D6CYP2C19RXRA
SCHEMBL4034223 0.72 GRM4 (0.51) NPC1ALDH1A1CYP2D6CYP2C19SYK
SCHEMBL5650346 0.72 IDO1 (0.49) HPGDTSHRMAOBMPOIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2006-03-23 US disclosed
EP-1545523-A1 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS Astex Technology Limited (GB) 2005-06-29 EP disclosed
WO-2005002673-A1 RAF KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed
WO-2004004720-A1 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors MAPK1, MAPK3, MAPK10 NPC1 1969/4885ALDH1A1 3196/4885CYP2D6 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.